Keyphrases
Cell-based
100%
Long-term Survival
100%
Melanoma Patients
100%
Tumor Antigen
100%
Survival Response
100%
Vaccination Therapy
100%
Antigen-presenting Cells
100%
Antigen-presenting
100%
Immune Dynamics
100%
Long-term Survivors
50%
Remission
50%
Demographic Parameters
25%
Delayed Hypersensitivity
25%
Lysate
25%
Cell Lysate
25%
Interleukin-17 (IL-17)
25%
Melanoma Cells
25%
Prolonged Survival
25%
Allogeneic
25%
Polymorphism
25%
Biological Markers
25%
Young Age
25%
Age-stage
25%
Survivors
25%
Immune Response
25%
Toll-like
25%
B Cells
25%
Phase II Trial
25%
CD4+ T Cells
25%
Reduced Survival
25%
Vaccine Response
25%
Member D
25%
Refractory Patients
25%
Immune Checkpoint Blockers
25%
Clinical Parameters
25%
Genetic Parameters
25%
C-type Lectin Domain
25%
Long-term Remission
25%
Cell-based Vaccine
25%
Stage III Disease
25%
Immunological Parameters
25%
Tumor Microenvironment
25%
CD32
25%
Cancer Vaccine
25%
Melanoma
25%
Immunomarkers
25%
Clinical Outcomes
25%
Medicine and Dentistry
Long Term Survival
100%
Immune Response
100%
Tumor Antigen
100%
Antigen Presenting Cell
100%
Melanoma
100%
Immunity
40%
Biological Marker
20%
Disease
20%
Melanoma Cell
20%
Delayed Hypersensitivity
20%
Allergic Response
20%
B Cell
20%
Interleukin 17
20%
Lectin
20%
Autoantigen
20%
Toll Like Receptor 4
20%
Tumor Microenvironment
20%
T-Helper Cell
20%
Biochemistry, Genetics and Molecular Biology
Dynamics
100%
Immune Response
100%
Long Term Survival
100%
Tumor Antigen
100%
Antigen Presenting Cell
100%
Cell Lysate
40%
Genetics
20%
Immunity
20%
T Cell
20%
C-Type Lectin
20%
B Cell
20%
Interleukin 17
20%
Immune Checkpoints
20%
Autoantigen
20%
Erethism
20%
TLR4
20%
CD4
20%
CD32
20%
INIS
dynamics
100%
patients
100%
therapy
100%
melanomas
100%
tumors
100%
antigens
100%
vaccines
42%
comparative evaluations
14%
diseases
14%
cancer
14%
genetics
14%
biological markers
14%
receptors
14%
heat
14%
refractories
14%
interleukins
14%
Immunology and Microbiology